BioCentury | Jan 9, 2006
Company News

SGX management update

...Diego, Calif. Business: Cancer, Computational chemistry/biology Hired: W. Todd Myers as CFO, formerly CFO at FeRx Inc....
BioCentury | Jan 9, 2006
Finance

Ebb & Flow

...last week, SGX hired Todd Myers as CFO. Previously, Myers was CFO of cancer company FeRx...
BioCentury | May 3, 2004
Clinical News

MTC-DOX: Phase II/III discontinued

...no longer seek a venture financing and will consider being acquired or closing its facilities. FeRx Inc....
BioCentury | Jul 14, 2003
Company News

FeRx board of directors update

FeRx Inc. , San Diego, Calif. Business: Cancer, Drug delivery Appointed: Michael George, president and CEO of Michael George & Associates WIR Staff...
BioCentury | Apr 7, 2003
Clinical News

FeRx preclinical data

...hour. Data were presented at the Society of Interventional Radiology meeting in Salt Lake City. FeRx Inc....
BioCentury | Apr 7, 2003
Clinical News

MTC-DOX: Phase I/II data; Phase II/III

...to the tumor via selective hepatic arterial catheterization, 31 of 33 patients had tumor localization. FeRx...
...11.5 months. Data were presented at the Society Interventional Radiology meeting in Salt Lake City. FeRx Inc....
BioCentury | Nov 25, 2002
Clinical News

MTC-DOX: Phase II/III

...started an international Phase II/III trial of MTC-DOX compared to intravenous doxyrubicin in 240 patients. FeRx Inc....
BioCentury | Nov 25, 2002
Tools & Techniques

Using magnets to fight cancer

...tumors will increase efficacy while reducing the serious cardiovascular side effects of doxorubicin. Last week FeRx...
...regulatory affairs. "The most common side effects were gastrointestinal and abdominal pain." To make MTC-DOX, FeRx...
...20 patients with metastatic liver cancer. MTC-DOX has U.S. Fast Track and Orphan Drug designation. FeRx...
BioCentury | Nov 25, 2002
Clinical News

MTC-DOX: Phase I/II

...patients had stable disease and 4 patients had progressive disease. Median survival was 11 months. FeRx...
...said historical data shows that intravenous doxorubicin gives survival of 3-6.5 months in similar patients. FeRx Inc....
BioCentury | Nov 25, 2002
Clinical News

MTC-DOX: Phase I/II

...and European Phase I/II repeat dosing study of MTC-DOX in 20 metastatic liver cancer patients. FeRx Inc....
Items per page:
1 - 10 of 37
BioCentury | Jan 9, 2006
Company News

SGX management update

...Diego, Calif. Business: Cancer, Computational chemistry/biology Hired: W. Todd Myers as CFO, formerly CFO at FeRx Inc....
BioCentury | Jan 9, 2006
Finance

Ebb & Flow

...last week, SGX hired Todd Myers as CFO. Previously, Myers was CFO of cancer company FeRx...
BioCentury | May 3, 2004
Clinical News

MTC-DOX: Phase II/III discontinued

...no longer seek a venture financing and will consider being acquired or closing its facilities. FeRx Inc....
BioCentury | Jul 14, 2003
Company News

FeRx board of directors update

FeRx Inc. , San Diego, Calif. Business: Cancer, Drug delivery Appointed: Michael George, president and CEO of Michael George & Associates WIR Staff...
BioCentury | Apr 7, 2003
Clinical News

FeRx preclinical data

...hour. Data were presented at the Society of Interventional Radiology meeting in Salt Lake City. FeRx Inc....
BioCentury | Apr 7, 2003
Clinical News

MTC-DOX: Phase I/II data; Phase II/III

...to the tumor via selective hepatic arterial catheterization, 31 of 33 patients had tumor localization. FeRx...
...11.5 months. Data were presented at the Society Interventional Radiology meeting in Salt Lake City. FeRx Inc....
BioCentury | Nov 25, 2002
Clinical News

MTC-DOX: Phase II/III

...started an international Phase II/III trial of MTC-DOX compared to intravenous doxyrubicin in 240 patients. FeRx Inc....
BioCentury | Nov 25, 2002
Tools & Techniques

Using magnets to fight cancer

...tumors will increase efficacy while reducing the serious cardiovascular side effects of doxorubicin. Last week FeRx...
...regulatory affairs. "The most common side effects were gastrointestinal and abdominal pain." To make MTC-DOX, FeRx...
...20 patients with metastatic liver cancer. MTC-DOX has U.S. Fast Track and Orphan Drug designation. FeRx...
BioCentury | Nov 25, 2002
Clinical News

MTC-DOX: Phase I/II

...patients had stable disease and 4 patients had progressive disease. Median survival was 11 months. FeRx...
...said historical data shows that intravenous doxorubicin gives survival of 3-6.5 months in similar patients. FeRx Inc....
BioCentury | Nov 25, 2002
Clinical News

MTC-DOX: Phase I/II

...and European Phase I/II repeat dosing study of MTC-DOX in 20 metastatic liver cancer patients. FeRx Inc....
Items per page:
1 - 10 of 37